Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
The Middle East Tapentadol Market, by Therapeutic Application (Pain Management (Neuropathic Pain, Cancer Pain, and Others), and Cough Treatment), and by Countries (KSA, UAE, Bahrain, Oman, Qatar, Israel, and Iran) was valued at US$ 0.86 million in 2016 and is projected to exhibit a CAGR of 6.1% during the forecast period (2017–2025).
Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/1054
The rising prevalence of pain-associated diseases such as cancer and diabetic neuropathy and unavailability of effective alternate therapy for management of neuropathic pain are expected to be the major factors driving growth of the Middle East tapentadol market during the forecast period. Janssen Pharmaceutical sold its license of marketing and distribution of the U.S. to Depomed, Inc. and in April 2017, Depomed, Inc. won the patent for tapentadol. Three ongoing clinical trials for tapentadol are being carried on for various indications and age groups.
Positive results from these trials is expected to cause the tapentadol market to gain rapid traction. Currently, tapentadol is only approved for consumption by adults and is not recommended for children due to its high therapeutic efficacy. However, one in three clinical trials are subjected to pediatric use. Grünenthal GmbH is carrying out an open-label trial, enrolling subjects aged 6 years to 18 years, which is estimated to be completed in December 2018. Another trial by St. Olavs Hospital is for pre- and post-operative pain relief after primary knee arthroplasty with the study estimated to complete in 2021.
Browse 10 Market Data Tables And 11 Figures Spread Through 106 Pages and In-depth TOC on Middle East Tapentadol Market, By Therapeutic Application (Pain Management (Neuropathic Pain, Cancer Pain, And Others), And Cough Treatment), and By Countries (KSA, UAE, Bahrain, Oman, Qatar, Israel, and Iran) – Forecast To 2025.
To know the latest trends and insights prevalent in the Middle East tapentadol market PRESS RELEASE, click the link below: https://www.coherentmarketinsights.com/press-release/middle-east-tapentadol-market-to-surpass-us-146-million-threshold-by-2025-469
Tapentadol can be used for various other applications, as it is also found to be the safest and best first-line treatment choice for advanced chronic kidney disease. However, clinical trials are still required for it to be prescribed for treatment. Furthermore, pilot studies have been performed on patients suffering from moderate-to-severe chronic back pain as published in the National Center for Biotechnology Information. The increasing number of off-label applications for this moderately addictive drug, along with low competition for existing indications, and robust pipelines are expected to boost growth of the tapentadol market during the forecast period.
Apply Promo Code “STAYHOME” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1054
Key Takeaways of the Middle East Tapentadol Market:
- The Middle East tapentadol market is expected to exhibit a CAGR of 6.1% during the forecast period (2017–2025), owing to the high prevalence of pain-related diseases in countries such as Iran, Palestine, and Kingdom of Saudi Arabia. For instance, according to the Journal of Taibah University Medical Sciences, the prevalence of diabetic neuropathic pain in Iran was 51.90% in 2016.
- Positive results of clinical trials of tapentadol are expected to drive growth of the tapentadol market further
- Absence of generic drugs after patent win by Depomed, Inc. in 2016, has reduced the competition
- Less likelihood of competition from opioids for neuropathic pain, as well as absence of any other opioid therapies undergoing research is expected to support growth of the market
- Some of the major players operating in the Middle East tapentadol market are Depomed, Inc., Janssen Pharmaceutical, Inc., Grünenthal, and Allergan, Plc.
Have a Look at Related Research Insights:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
